CSBio CSBio

X
[{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Iovance Biotherapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"T3 Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","amount":"$27.4 million","upfrontCash":"Undisclosed","newsHeadline":"T3 Pharma Raises 25M CHF to Advance Bacterial Cancer Therapy Through Clinic","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"T3 Pharma"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Basilea Announces Data Presentations at ESMO Virtual Congress 2020","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"Lonza Group","sponsor":"LamKap Bio Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"LamKap Bio Group and Lonza Collaborate to Manufacture Bispecific Antibodies for Cancer Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Lonza Group"},{"orgOrder":0,"company":"Lonza Group","sponsor":"PsiVac","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"PsiVac and Lonza Enter a Strategic Agreement for the Process Development and cGMP Manufacturing of Ixovex-1","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Lonza Group"},{"orgOrder":0,"company":"Nouscom AG","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Nouscom Receives Approval to Begin Phase 1b Trials of NOUS-PEV, a Novel Personalized Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Nouscom AG"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Araris Biotech AG to Present at 12th Annual World ADC Digital Conference","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"Undisclosed","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Araris Biotech"},{"orgOrder":0,"company":"ImmunOs Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"ImmunOs Therapeutics\u00b4 Lead Program Shows Strong Anti-Tumor Activity In Vivo and In Vitro","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"ImmunOs Therapeutics"},{"orgOrder":0,"company":"Vaximm AG","sponsor":"NEC OncoImmunity","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NEC OncoImmunity Acquires VAXIMM's Neoantigen Vaccine Development Assets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Vaximm AG"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Araris Biotech AG to Present Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2022","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Araris Biotech"},{"orgOrder":0,"company":"CDR Life","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"CDR-Life to Present at the American Association for Cancer Research 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"CDR Life"},{"orgOrder":0,"company":"CDR Life","sponsor":"Jeito Capital","pharmaFlowCategory":"D","amount":"$76.0 million","upfrontCash":"Undisclosed","newsHeadline":"CDR-Life Announces $76 Million Raised in Series A Funding","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"CDR Life"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Araris Biotech AG Presents Preclinical Data Highlighting Anti-CD79b ADC Program and Late-Breaking Data on Nectin-4 ADC at the American Association for Cancer Research (AACR) 2022 Annual Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Araris Biotech"},{"orgOrder":0,"company":"TargImmune Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TargImmune Announces Successful Completion of GLP\/Tox Studies and Further Reinforcement of Leadership Team with Hire of Head of Technical Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"TargImmune Therapeutics"},{"orgOrder":0,"company":"Gnubiotics Sciences","sponsor":"Swiss Innovation Agency","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Gnubiotics Sciences Announces Funding from the Swiss Innovation Agency to Accelerate Development of Glycopeptide Mediated Immunotherapies Against Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Gnubiotics Sciences"},{"orgOrder":0,"company":"Spexis","sponsor":"University of Michigan","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spexis' CXCR4 Inhibitor Balixafortide Demonstrates Synergistic Efficacy in Combination With Docetaxel in a Metastatic Prostate Cancer Preclinical Model","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Spexis"},{"orgOrder":0,"company":"Mymetics","sponsor":"PCI Biotech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Mymetics and PCI Biotech Sign a Preclinical Research Collaboration","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Mymetics"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"SillaJen, Inc","pharmaFlowCategory":"D","amount":"$334.0 million","upfrontCash":"Undisclosed","newsHeadline":"Basilea Announces Acquisition of Rights for Oncology Asset BAL0891 by SillaJen And Updates Financial Guidance","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Araris Biotech AG to Present at Informa Connect\u2019s Next Generation Protein Therapeutics Summit","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Araris Biotech"},{"orgOrder":0,"company":"Basilea Pharmaceutica","sponsor":"Twentyeight-Seven Therapeutics","pharmaFlowCategory":"D","amount":"$357.9 million","upfrontCash":"$1.0 million","newsHeadline":"Basilea Announces Sale Of Preclinical Oncology Program To Twentyeight-Seven Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Basilea Pharmaceutica"},{"orgOrder":0,"company":"Spexis","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Spexis Announces Promising Pre-clinical Data With Balixafortide In Combination With Various Therapies On The Market For Treating B-cell Lymphomas","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Peptide","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Peptide","graph2":"Spexis"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Araris Biotech AG to Present at the 22nd Annual PepTalk: Protein Science and Production Week","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Araris Biotech"},{"orgOrder":0,"company":"Ymmunobio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Ymmunobio's CEACAM Antibody for the Treatment of Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Ymmunobio"},{"orgOrder":0,"company":"Laevoroc Oncology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Laevoroc Immunology Announces FDA Orphan Drug Designation Granted to LR 09, a Novel Metabolic Immune Checkpoint Inhibitor for the Treatment of Leukemia Relapse after Allogeneic Stem Cell Transplant","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Laevoroc Oncology"},{"orgOrder":0,"company":"Lonza Group","sponsor":"ABL Bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Lonza and ABL Bio Collaborate in the Development and Manufacture of Bispecific Antibody Product","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Lonza Group"},{"orgOrder":0,"company":"Ionctura","sponsor":"Clavius Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iOnctura and Clavius Exercise Option for TGF-\u03b2 Pathway Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Ionctura"},{"orgOrder":0,"company":"Ionctura","sponsor":"Health Holland","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"iOnctura Expands Pipeline And Receives Development Grant From Health Holland And KWF","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Ionctura"},{"orgOrder":0,"company":"Araris Biotech","sponsor":"Innosuisse","pharmaFlowCategory":"D","amount":"$2.8 million","upfrontCash":"Undisclosed","newsHeadline":"Araris Biotech AG Supported with CHF 2.5M Swiss Accelerator Grant from Innosuisse to Develop Antibody-Drug Conjugate Candidates","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Large molecule","graph2":"Araris Biotech"},{"orgOrder":0,"company":"Tolremo therapeutics","sponsor":"Pierre Fabre Invest","pharmaFlowCategory":"D","amount":"$39.0 million","upfrontCash":"Undisclosed","newsHeadline":"TOLREMO Therapeutics Completes USD 39 Million Series A Financing Round with Strategic Investment from Pierre Fabre Invest","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Tolremo therapeutics"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Large molecule","graph2":"Numab Therapeutics"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Through collaboration, Ono has obtained rights for NM49 from Numab for global development and commercialization, which is a multi-specific antibody designed to activate tumor-associated macrophage phagocytosis for the treatment of cancers.

            Lead Product(s): NM49

            Therapeutic Area: Oncology Product Name: NM49

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Ono Pharmaceutical

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration February 14, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The funding will accelerate the company's lead program, TT125-802, an orally available small molecule CBP/p300 bromodomain inhibitor, into a first-in-human study in patients with solid tumors.

            Lead Product(s): TT125-802

            Therapeutic Area: Oncology Product Name: TT125-802

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Pierre Fabre Invest

            Deal Size: $39.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing September 20, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Araris’ awarded grant will be used to support further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates. Araris’ ADC linker technology enables payload attachment to off the shelf antibodies without needing to re-engineer or reduce antibodies.

            Lead Product(s): Antibody-drug Conjugate

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Innosuisse

            Deal Size: $2.8 million Upfront Cash: Undisclosed

            Deal Type: Funding May 05, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the agreement, iOnctura gets exclusive global development rights to IOA-359, a novel oral, small molecule, TGF–β pathway inhibitor that will be evaluated in solid tumors.

            Lead Product(s): IOA-359

            Therapeutic Area: Oncology Product Name: IOA-359

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Clavius Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement May 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The grant will accelerate iOnctura's preclinical investigation of IOA-359, a novel oral, small molecule, TGF–β pathway inhibitor that will be evaluated in solid tumors.

            Lead Product(s): IOA-359

            Therapeutic Area: Oncology Product Name: IOA-359

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Health Holland

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Funding May 03, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The collaboration supports the development and manufacturing of ABL Bio’s new bispecific antibody product by leveraging Lonza’s GS Xceed® expression system which includes GS PiggyBac®, a highly efficient transposon-based gene integration technology.

            Lead Product(s): Bispecific Antibody

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: ABL Bio

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration April 04, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            YB-200 belongs to a novel class of CEACAM1 antibodies with a dual action. It acts as a checkpoint inhibitor, but also has a direct immune agonistic effect on immune cells. It is being studying for the treatment of hepatocellular carcinoma (HCC).

            Lead Product(s): YB-200

            Therapeutic Area: Oncology Product Name: YB-200

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 28, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            LR 09 is a novel salt form of the small molecule drug, ulodesine, is a PNP inhibitor which is in preclinical development for the treatment of leukemia relapse following allogeneic stem cell transplantation.

            Lead Product(s): LR 09

            Therapeutic Area: Oncology Product Name: LR 09

            Highest Development Status: Preclinical Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 28, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            ARC-02 demonstrated potent cytotoxicity in three different non-Hodgkin Lymphoma (NHL) cell lines, with similar potency to Polivy® despite ARC-02’s having a lower drug load.

            Lead Product(s): ARC-02

            Therapeutic Area: Oncology Product Name: ARC-02

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 19, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Balixafortide (POL6326), is a potent, specific and highly selective macrocycle inhibitor of CXCR4 that plays a role in a number of tumor types as well as non-oncology indications.

            Lead Product(s): Balixafortide,Undisclosed

            Therapeutic Area: Oncology Product Name: POL6326

            Highest Development Status: Preclinical Product Type: Peptide

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 13, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY